The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
18 nov. 2021 07h00 HE
|
Amicus Therapeutics, Inc.
Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed...
Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
11 nov. 2021 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel...
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
09 nov. 2021 07h00 HE
|
Amicus Therapeutics, Inc.
3Q21 Total Galafold® Revenue of $79.5M – an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance of $300M-$315M AT-GAA BLA and NDA for Pompe Disease Accepted for Review by the...
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
03 nov. 2021 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at...
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
29 sept. 2021 06h30 HE
|
Amicus Therapeutics, Inc.
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding ...
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
29 sept. 2021 06h30 HE
|
Amicus Therapeutics, Inc.
FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application and July 29, 2022 for the Biologics License Application On Track for MAA Submission in the Fourth Quarter of this Year ...
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
20 sept. 2021 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
03 sept. 2021 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at...
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
05 août 2021 07h00 HE
|
Amicus Therapeutics, Inc.
2Q21 Total Galafold® (migalastat) Revenue of $77.4M, a 24% increase over 2Q20 On-Track to Achieve Revenue Guidance of $300M-$315M Completed the Rolling BLA and NDA Submissions to the U.S. FDA for...
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
04 août 2021 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG...